Halobetasol Propionate Foam vs Halobetasol Propionate Lotion
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: Glucocorticoid receptor · full Psoriasis pipeline
Halobetasol Propionate Foam · Lexette
Rights held by Mayne Pharma; US product discontinued
NCT02742441 · Phase 3 · completed
The trial randomized 409 participants to active foam or vehicle foam and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical endpoint was met, with treatment success in 30.7% versus 7.4% of participants at Day 15 (p<0.001).
Reported efficacy
Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): 122-0551 Foam 30.7% vs Vehicle Foam 7.4% (met)
Result source: NCT02742441
Halobetasol Propionate Lotion · Bryhali
Marketed by Bausch Health
NCT02514577 · Phase 3 · completed
The study was randomized, quadruple-blinded and vehicle-controlled, with 217 participants, and used a clinical Investigator's Global Assessment treatment-success endpoint at Week 8. The peer-reviewed report of the two Phase 3 trials states superiority over vehicle at Week 8 (36.5% (Study 1) vs vehicle, P<0.001), so the primary comparison was met.
Reported efficacy
Percentage of Participants With Treatment Success at Week 8: Percentage of Participants With Treatment Success at Week 8 (Week 8): IDP-122 Lotion 36.5% vs IDP-122 Vehicle Lotion 8.13% (met)
Result source: NCT02514577
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Halobetasol Propionate Foam | Halobetasol Propionate Lotion |
|---|---|---|
| PASI 75 | —Not posted · NCT02367911 | —Not reported |
| PASI 90 | —Not posted · NCT02367911 | —Not reported |
| PASI 100 | —Not posted · NCT02367911 | —Not reported |
| sPGA 0/1 | —Not posted · NCT02367911 | 36.5% vs 8.1%+28.4 vs placeboNCT025145779 other results
|
| DLQI, change | —Not posted · NCT02367911 | —Not reported |
PASI 75
- Halobetasol Propionate Foam
- —Not posted · NCT02367911
- Halobetasol Propionate Lotion
- —Not reported
PASI 90
- Halobetasol Propionate Foam
- —Not posted · NCT02367911
- Halobetasol Propionate Lotion
- —Not reported
PASI 100
- Halobetasol Propionate Foam
- —Not posted · NCT02367911
- Halobetasol Propionate Lotion
- —Not reported
sPGA 0/1
- Halobetasol Propionate Foam
- —Not posted · NCT02367911
- Halobetasol Propionate Lotion
- 36.5% vs 8.1%+28.4 vs placeboNCT02514577
9 other results
- 38.4% vs 12.0% NCT02515097
- 19.5% vs 6.7% NCT02514577
- 23.0% vs 9.3% NCT02515097
- 30.1% vs 7.9% NCT02514577
- 27.7% vs 4.3% NCT02515097
- 19.8% vs 2.8% NCT02514577
- 19.3% vs 0.2% NCT02515097
- 7.1% vs 0% NCT02514577
- 4.9% vs 0% NCT02515097
DLQI, change
- Halobetasol Propionate Foam
- —Not posted · NCT02367911
- Halobetasol Propionate Lotion
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. Halobetasol Propionate Foam: 6 of 6 rows · Halobetasol Propionate Lotion: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Halobetasol Propionate Foam Rows use multiple source trials | Halobetasol Propionate Lotion |
|---|---|---|
| BSA absolute change · percentage points Induction | -1.5% (n=199) vs -0.2% (n=196) placebo @ 2.14wka,b,c NCT02742441 · Phase 3 1 other source trial-1.3% (n=23) vs 0% (n=20) placebo @ 2.14wk NCT01700985 · Phase 2 · registry result, not featured evidence | -1.3% (n=36) vs -0.2% (n=35) placebo @ 2.14wk0.05% lotiona,b,c NCT01610596 · Phase 2 · registry result, not featured evidence |
| PGA 2-point Improvement responder rate · % of participants Induction | 52.2% (n=23) vs 0% (n=20) placebo @ 2.14wkb,c NCT01700985 · Phase 2 · registry result, not featured evidence | 44.4% (n=36) vs 0% (n=35) placebo @ 2.14wk0.05% lotionb,c NCT01610596 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 2.9%d NCT02742441 · Phase 3 show 4 more results1.3% NCT02368210 · Phase 3 7% NCT02367911 · Phase 3 0% NCT01698333 · Phase 2 · registry result, not featured evidence 0% NCT01700985 · Phase 2 · registry result, not featured evidence | 9.8%e NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3 show 2 more results4.9% NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3 0%0.05% lotion NCT01610596 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0%d NCT02742441 · Phase 3 show 4 more results0% NCT02368210 · Phase 3 — NCT02367911 · Phase 3 — NCT01698333 · Phase 2 · registry result, not featured evidence — NCT01700985 · Phase 2 · registry result, not featured evidence | 0.7%e NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3 show 2 more results1.4% NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3 —0.05% lotion NCT01610596 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%d NCT02742441 · Phase 3 show 4 more results0% NCT02368210 · Phase 3 0% NCT02367911 · Phase 3 0% NCT01698333 · Phase 2 · registry result, not featured evidence 0% NCT01700985 · Phase 2 · registry result, not featured evidence | 0.7%e NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3 show 2 more results1.4% NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3 0%0.05% lotion NCT01610596 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | d headache 1.5% (placebo 1.5%) application site pain 1% (placebo 0.5%) back pain 0.5% (placebo 0%) NCT02742441 · Phase 3 show 4 more resultsabdominal pain 1.3% (placebo 0%) application site pain 1.3% (placebo 0%) hordeolum 1.3% (placebo 0%) NCT02368210 · Phase 3 sinusitis 1.4% (placebo 0%) trichorrhexis 1.4% (placebo 0%) application site dryness 0% (placebo 1.4%) NCT02367911 · Phase 3 acth stimulation test abnormal 24% nasal congestion 4% pharyngitis 4% NCT01698333 · Phase 2 · registry result, not featured evidence influenza like illness 4.3% (placebo 0%) pharyngitis 0% (placebo 4.8%) upper respiratory tract infection 0% (placebo 9.5%) NCT01700985 · Phase 2 · registry result, not featured evidence | 0.05% lotione application site pain 8.3% (placebo 8.3%) application site atrophy 5.6% (placebo 0%) application site discoloration 2.8% (placebo 0%) NCT01610596 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dPopulation comparability has not been reviewed for these studies.
- ePopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Halobetasol Propionate Foam
show 2 more results
show 4 more results
show 1 more result
show 1 more result
show 1 more result
Halobetasol Propionate Lotion
show 9 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Halobetasol Propionate Foam's landscape · Halobetasol Propionate Lotion's landscape